Bernard Parker is senior vice president, global commercialization at Mirum Pharmaceuticals, where he leads the company’s commercialization strategy and global launch planning.
Bernard brings more than 20 years of commercialization, corporate development and growth strategy experience. Most recently, he was a vice president with Ionis Pharmaceuticals and its commercial affiliate Akcea Therapeutics. During his tenure at Ionis/Akcea, Bernard oversaw commercial planning and global launch preparation for a portfolio of rare disease product candidates. Prior to that, he held multiple U.S., Europe and global commercial leadership positions at Novartis, Ignyta, Amgen and Parke-Davis/Warner Lambert/Pfizer. Bernard has deep experience in both the US and international markets, including long-term assignments based in Switzerland and Germany, as well as broad therapeutic area experience spanning a range of indications and genetically-defined orphan disorders. Earlier in his career, Bernard was a management consultant at Bain & Company, where he worked on corporate strategy and private equity engagements.
Bernard holds a B.A. in Biology from Hampton University and an MBA from Harvard Business School.